Literature DB >> 7647343

Western blotting and isoform analysis of cathepsin D from normal and malignant human breast cell lines.

L D Laury-Kleintop1, E C Coronel, M K Lange, T Tachovsky, S Longo, S Tucker, J A Alhadeff.   

Abstract

Cathepsin D from normal (Hs578Bst) and malignant (MCF7, MDA-MB-231) breast cell lines has been characterized with regard to its kinetic properties, activity levels, precursor and processed M(r) forms, and isoform composition. Normal cell cathepsin D appears to have a more neutral pH optimum (pH 3.5) than the cancer cell line (pH 3.0-3.2) and greater activity between pH values of 4.0 to 4.5. The two cancer cell lines have approximately 1.5 to 2.0-fold increased total acid protease activity and 2 to 3-fold increased pepstatin-inhibitable protease activity (i.e. cathepsin D) when compared to the normal breast cell line. Western blotting indicates that a major processed form of cathepsin D for all three cell lines occurs at 31 kDa. The cancer cell lines contain significant amounts of cathepsin D precursors of 47 and 42 kDa whereas the normal cell line contains little if any of these precursors. Isoelectric focusing indicates that the normal cell line contains approximately 50% of its total acid protease activity at pIs above 4 whereas the cancer cell lines contain 70-80% of their protease activity at such pIs. In addition, the cancer cell lines contain two to three major isoforms between pIs of 5.5 and 6.3 which were not present in the normal cell line. The isoforms from pI values of 5.5 to 7.3 for all three cell lines are 100% pepstatin-inhibitable. In addition, Western blot analysis indicates that these isoforms contain the processed 31 kDa form of cathepsin D. The combined results indicate that the two breast cancer cell lines are similar to biopsied malignant breast tissue in exhibiting altered acid protease isoform profiles with increased relative amounts of pepstatin-inhibitable and immunoreactive acid protease activity (cathepsin D) compared to normal breast tissue or cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647343     DOI: 10.1007/bf00668211

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells.

Authors:  F Capony; C Rougeot; P Montcourrier; V Cavailles; G Salazar; H Rochefort
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells.

Authors:  I Touitou; V Cavaillès; M Garcia; A Defrenne; H Rochefort
Journal:  Mol Cell Endocrinol       Date:  1989-10       Impact factor: 4.102

Review 4.  Cathepsin D in the malignant progression of neoplastic diseases (review).

Authors:  G Leto; N Gebbia; L Rausa; F M Tumminello
Journal:  Anticancer Res       Date:  1992 Jan-Feb       Impact factor: 2.480

5.  Biological and clinical significance of cathepsin D in breast cancer.

Authors:  H Rochefort
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

6.  In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.

Authors:  P Briozzo; M Morisset; F Capony; C Rougeot; H Rochefort
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

7.  Hormonal regulation of cathepsin D following transfection of the estrogen or progesterone receptor into three sex steroid hormone resistant cancer cell lines.

Authors:  I Touitou; F Vignon; V Cavailles; H Rochefort
Journal:  J Steroid Biochem Mol Biol       Date:  1991       Impact factor: 4.292

8.  Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.

Authors:  T E Kute; Z M Shao; N K Sugg; R T Long; G B Russell; L D Case
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

9.  Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

Authors:  V Cavailles; P Augereau; M Garcia; H Rochefort
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

10.  Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells.

Authors:  V Cavaillès; P Augereau; H Rochefort
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more
  4 in total

1.  HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency.

Authors:  Li Mao; Kelsey J Wertzler; Scott C Maloney; Zeping Wang; Nancy S Magnuson; Raymond Reeves
Journal:  Mol Cell Biol       Date:  2009-08-17       Impact factor: 4.272

Review 2.  Possible role of procathepsin D in human cancer.

Authors:  A Vashishta; M Fusek; V Vetvicka
Journal:  Folia Microbiol (Praha)       Date:  2005       Impact factor: 2.629

3.  Proteomic evaluation and validation of cathepsin D regulated proteins in macrophages exposed to Streptococcus pneumoniae.

Authors:  Martin A Bewley; Trong K Pham; Helen M Marriott; Josselin Noirel; Hseuh-Ping Chu; Saw Y Ow; Alexey G Ryazanov; Robert C Read; Moira K B Whyte; Benny Chain; Phillip C Wright; David H Dockrell
Journal:  Mol Cell Proteomics       Date:  2011-04-07       Impact factor: 5.911

4.  Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis.

Authors:  Benny Zhitomirsky; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2017-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.